229 related articles for article (PubMed ID: 28369050)
1. Antagonism of B cell enhancer networks by STAT5 drives leukemia and poor patient survival.
Katerndahl CDS; Heltemes-Harris LM; Willette MJL; Henzler CM; Frietze S; Yang R; Schjerven H; Silverstein KAT; Ramsey LB; Hubbard G; Wells AD; Kuiper RP; Scheijen B; van Leeuwen FN; Müschen M; Kornblau SM; Farrar MA
Nat Immunol; 2017 Jun; 18(6):694-704. PubMed ID: 28369050
[TBL] [Abstract][Full Text] [Related]
2. Ebf1 or Pax5 haploinsufficiency synergizes with STAT5 activation to initiate acute lymphoblastic leukemia.
Heltemes-Harris LM; Willette MJ; Ramsey LB; Qiu YH; Neeley ES; Zhang N; Thomas DA; Koeuth T; Baechler EC; Kornblau SM; Farrar MA
J Exp Med; 2011 Jun; 208(6):1135-49. PubMed ID: 21606506
[TBL] [Abstract][Full Text] [Related]
3. Sleeping Beauty transposon screen identifies signaling modules that cooperate with STAT5 activation to induce B-cell acute lymphoblastic leukemia.
Heltemes-Harris LM; Larson JD; Starr TK; Hubbard GK; Sarver AL; Largaespada DA; Farrar MA
Oncogene; 2016 Jun; 35(26):3454-64. PubMed ID: 26500062
[TBL] [Abstract][Full Text] [Related]
4. Superenhancer reprogramming drives a B-cell-epithelial transition and high-risk leukemia.
Hu Y; Zhang Z; Kashiwagi M; Yoshida T; Joshi I; Jena N; Somasundaram R; Emmanuel AO; Sigvardsson M; Fitamant J; El-Bardeesy N; Gounari F; Van Etten RA; Georgopoulos K
Genes Dev; 2016 Sep; 30(17):1971-90. PubMed ID: 27664237
[TBL] [Abstract][Full Text] [Related]
5. BLNK suppresses pre-B-cell leukemogenesis through inhibition of JAK3.
Nakayama J; Yamamoto M; Hayashi K; Satoh H; Bundo K; Kubo M; Goitsuka R; Farrar MA; Kitamura D
Blood; 2009 Feb; 113(7):1483-92. PubMed ID: 19047679
[TBL] [Abstract][Full Text] [Related]
6. ZFP521 contributes to pre-B-cell lymphomagenesis through modulation of the pre-B-cell receptor signaling pathway.
Hiratsuka T; Takei Y; Ohmori R; Imai Y; Ozeki M; Tamaki K; Haga H; Nakamura T; Tsuruyama T
Oncogene; 2016 Jun; 35(25):3227-38. PubMed ID: 26522721
[TBL] [Abstract][Full Text] [Related]
7. EBF1 and Pax5 safeguard leukemic transformation by limiting IL-7 signaling, Myc expression, and folate metabolism.
Ramamoorthy S; Kometani K; Herman JS; Bayer M; Boller S; Edwards-Hicks J; Ramachandran H; Li R; Klein-Geltink R; Pearce EL; Grün D; Grosschedl R
Genes Dev; 2020 Nov; 34(21-22):1503-1519. PubMed ID: 33004416
[No Abstract] [Full Text] [Related]
8. Ikaros antagonizes DNA binding by STAT5 in pre-B cells.
Heizmann B; Le Gras S; Simand C; Marchal P; Chan S; Kastner P
PLoS One; 2020; 15(11):e0242211. PubMed ID: 33180866
[TBL] [Abstract][Full Text] [Related]
9. Activation of NF-kappaB p50/p65 is regulated in the developing mammary gland and inhibits STAT5-mediated beta-casein gene expression.
Geymayer S; Doppler W
FASEB J; 2000 Jun; 14(9):1159-70. PubMed ID: 10834938
[TBL] [Abstract][Full Text] [Related]
10. LCK over-expression drives STAT5 oncogenic signaling in PAX5 translocated BCP-ALL patients.
Cazzaniga V; Bugarin C; Bardini M; Giordan M; te Kronnie G; Basso G; Biondi A; Fazio G; Cazzaniga G
Oncotarget; 2015 Jan; 6(3):1569-81. PubMed ID: 25595912
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-7 signaling in human B cell precursor acute lymphoblastic leukemia cells and murine BAF3 cells involves activation of STAT1 and STAT5 mediated via the interleukin-7 receptor alpha chain.
van der Plas DC; Smiers F; Pouwels K; Hoefsloot LH; Löwenberg B; Touw IP
Leukemia; 1996 Aug; 10(8):1317-25. PubMed ID: 8709637
[TBL] [Abstract][Full Text] [Related]
12. Deregulation of kinase signaling and lymphoid development in EBF1-PDGFRB ALL leukemogenesis.
Welsh SJ; Churchman ML; Togni M; Mullighan CG; Hagman J
Leukemia; 2018 Jan; 32(1):38-48. PubMed ID: 28555080
[TBL] [Abstract][Full Text] [Related]
13. Co-existence of IL7R high and SH2B3 low expression distinguishes a novel high-risk acute lymphoblastic leukemia with Ikaros dysfunction.
Ge Z; Gu Y; Xiao L; Han Q; Li J; Chen B; Yu J; Kawasawa YI; Payne KJ; Dovat S; Song C
Oncotarget; 2016 Jul; 7(29):46014-46027. PubMed ID: 27322554
[TBL] [Abstract][Full Text] [Related]
14. IRF8 regulates B-cell lineage specification, commitment, and differentiation.
Wang H; Lee CH; Qi C; Tailor P; Feng J; Abbasi S; Atsumi T; Morse HC
Blood; 2008 Nov; 112(10):4028-38. PubMed ID: 18799728
[TBL] [Abstract][Full Text] [Related]
15. Ikaros regulation of the BCL6/BACH2 axis and its clinical relevance in acute lymphoblastic leukemia.
Ge Z; Zhou X; Gu Y; Han Q; Li J; Chen B; Ge Q; Dovat E; Payne JL; Sun T; Song C; Dovat S
Oncotarget; 2017 Jan; 8(5):8022-8034. PubMed ID: 28030830
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of high c-MYC and low MYCBP2 expression and their association with Ikaros dysfunction in adult acute lymphoblastic leukemia.
Ge Z; Guo X; Li J; Hartman M; Kawasawa YI; Dovat S; Song C
Oncotarget; 2015 Dec; 6(39):42300-11. PubMed ID: 26517351
[TBL] [Abstract][Full Text] [Related]
17. Pre-B cell receptor-mediated cell cycle arrest in Philadelphia chromosome-positive acute lymphoblastic leukemia requires IKAROS function.
Trageser D; Iacobucci I; Nahar R; Duy C; von Levetzow G; Klemm L; Park E; Schuh W; Gruber T; Herzog S; Kim YM; Hofmann WK; Li A; Storlazzi CT; Jäck HM; Groffen J; Martinelli G; Heisterkamp N; Jumaa H; Müschen M
J Exp Med; 2009 Aug; 206(8):1739-53. PubMed ID: 19620627
[TBL] [Abstract][Full Text] [Related]
18. Pax5 loss imposes a reversible differentiation block in B-progenitor acute lymphoblastic leukemia.
Liu GJ; Cimmino L; Jude JG; Hu Y; Witkowski MT; McKenzie MD; Kartal-Kaess M; Best SA; Tuohey L; Liao Y; Shi W; Mullighan CG; Farrar MA; Nutt SL; Smyth GK; Zuber J; Dickins RA
Genes Dev; 2014 Jun; 28(12):1337-50. PubMed ID: 24939936
[TBL] [Abstract][Full Text] [Related]
19. STAT5 in B cell development and leukemia.
Malin S; McManus S; Busslinger M
Curr Opin Immunol; 2010 Apr; 22(2):168-76. PubMed ID: 20227268
[TBL] [Abstract][Full Text] [Related]
20. PAX5 is part of a functional transcription factor network targeted in lymphoid leukemia.
Okuyama K; Strid T; Kuruvilla J; Somasundaram R; Cristobal S; Smith E; Prasad M; Fioretos T; Lilljebjörn H; Soneji S; Lang S; Ungerbäck J; Sigvardsson M
PLoS Genet; 2019 Aug; 15(8):e1008280. PubMed ID: 31381561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
